The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The Spruce clinical trial: Double-blind randomized phase II trial of carboplatin and pemetrexed +/- apatorsen in patients with previously untreated stage IV non-squamous non-small-cell lung cancer.
 
Dianna Shipley
No Relationships to Disclose
 
David Michael Waterhouse
Consulting or Advisory Role - Bristol-Myers Squibb; Lilly
Speakers' Bureau - Bristol-Myers Squibb; Celgene; Genentech/Roche; Lilly
 
Suzanne Fields Jones
No Relationships to Disclose
 
Dawn Michelle Stults
No Relationships to Disclose
 
Patrick J. Ward
No Relationships to Disclose
 
Kent C. Shih
Honoraria - Genentech
 
Michael Brian Hemphill
No Relationships to Disclose
 
Michael McCleod
No Relationships to Disclose
 
Robert C. Whorf
No Relationships to Disclose
 
Ray D. Page
Employment - The Center for Cancer and Blood Disorders
Stock and Other Ownership Interests - Oncology Metrics
Honoraria - Astellas Pharma
Consulting or Advisory Role - via oncology
Speakers' Bureau - AmerisourceBergen; Biodesix
Research Funding - Sarah Cannon Research Institute
Travel, Accommodations, Expenses - RainTree Oncology Services
 
Joesph Stilwell
No Relationships to Disclose
 
Tarek Mekhail
No Relationships to Disclose
 
Kirsten Anderson
Employment - OncoGenex
 
Cindy Jacobs
Employment - OncoGenex
 
John D. Hainsworth
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Celgene (Inst); Genentech (Inst); Johnson & Johnson (Inst); Lilly (Inst); Novartis (Inst)
 
David R. Spigel
Stock and Other Ownership Interests - Foundation Medicine; Illumina
Consulting or Advisory Role - AstraZeneca; Biodesix; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Clovis Oncology; Genentech/Roche; Lilly; Novartis; Pfizer
Speakers' Bureau - Novartis
Research Funding - Amgen (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); BIND Biosciences (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Clovis Oncology (Inst); CytRx Corporation (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Genentech/Roche (Inst); ImClone Systems (Inst); Immunogen (Inst); Lilly (Inst); Novartis (Inst); Oncogenex (Inst); OncoMed (Inst); Peregrine Pharmaceuticals (Inst); Pfizer (Inst); University of Texas Southwestern Medical Center - Simmons Cancer Center (Inst); Verastem (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Biodesix; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Clovis Oncology; Genentech/Roche; Lilly; Novartis; Pfizer